Table 1.
Select Drug Combination Nanoparticle Powder (DcNP) Compositions Evaluated For the Formation of Multi-Drug-Motif Structures.a
| DcNP (Tested) | Hydrophilic Drugs (Log P<1) |
Hydrophobic Drugs (Log P>2) |
Multi-Drug-Motif (MDM) Structure | ||
|---|---|---|---|---|---|
| Lamivudine | Tenofovir | Lopinavir | Ritonavir | ||
| Reference | − | + | + | + | Yesb |
| Variant-1 | + | + | + | + | Yes |
| Variant-2 | − | + | − | − | Yes |
| Variant-3 | − | − | + | + | Yes |
| Variant-4 | − | − | + | − | Noc |
| Lamivudine | Tenofovir | Dolutegravir | Rilpivirine | ||
|
| |||||
| Variant-5 | + | + | + | + | Yes |
| Variant-6 | + | + | + | − | Yes |
a
A partial list of drug combinations with respective antiretroviral APIs were tested using the controlled solvent removal method as described. The resulting DcNP powder products were evaluated with PXRD for formation of MDM repeating units in powder form.
b
Yes, indicates formation ofMDM structure as evaluated by PXRD diffraction signature for MDM similar to the lead or “Reference” composition as presented in Fig. 1, panel I.
c
No, indicates the PXRD diffraction pattern retains significant signature of API or excipient profile.